Discovery of ganodecalone A, from Ganoderma calidophilum for the treatment of acute gastric ulcers by binding to ALOX5 via the MAPK/NF-κB/iNOS signaling

Abstract

Ethnopharmacological relevance: "Li medicine" Ganoderma calidophilum is a rare and unique medicinal fungus native to Hainan, China, traditionally used to relieve stomach pain and treat gastric diseases. However, its medicinal applications lack scientific validation despite its prominent role in ethnomedicine.

Aim of the study: This study aimed to evaluate the therapeutic potential of G. calidophilum extract against gastric ulcer (GU), isolate its main bioactive compound (GDA), and elucidate the underlying mechanisms of action.

Materials and methods: In vivo, acute gastric mucosal-injured mice were observed for mucosal symptoms, and levels of IL-6, TNF-α, SOD, and MDA were measured. In vitro, ethanol-damaged GES-1 cells were used to test the effects of G. calidophilum extract and GDA. 28 compounds were isolated from the extract, and network pharmacology and molecular docking studied GDA influence on ALOX5 and NF-κB.

Results: The extract improved mouse symptoms regulated inflammatory and oxidative stress markers. GDA, the key anti-inflammatory compound, repaired cell damage, reduced inflammation and oxidative stress. Network and docking results showed GDA inhibited early-stage inflammation.

Conclusions: G. calidophilum extract exhibits potent anti-GU activity, primarily attributed to GDA, which alleviates gastric mucosal inflammation by binding to ALOX5 and modulating MAPK/NF-κB/iNOS signaling and lipid peroxidation. These findings validate its traditional use and provide a mechanistic basis for its therapeutic application in acute GU.

Keywords: Ganodecalone A; Ganoderma calidophilum; Gastric ulcer; Inflammation; MAPK/NF-κB/iNOS signalling; Oxidative stress.